ライフサイエンスコーパス: disability

1 are linked to tumorigenesis and intellectual disability.

2 h short stature, cataracts, and intellectual disability.

3 ing rather than an increase in prevalence of disability.

4 ey are among the leading causes of death and disability.

5 ed childhood-onset epilepsy and intellectual disability.

6 of autism spectrum disorder and intellectual disability.

7 s often results in major injury and lifelong disability.

8 nked to epileptic disorders and intellectual disability.

9 4150 (69.6%) DALYs were attributed to disability.

10 ic, autosomal recessive form of intellectual disability.

11 ic burden for schizophrenia and intellectual disability.

12 most frequent genetic cause of intellectual disability.

13 comprehension deficit, and language learning disability.

14 stic features and mostly severe intellectual disability.

15 adherence, and thereby reduce CVD death and disability.

16 s in patients with epilepsy and intellectual disability.

17 o clinically definite multiple sclerosis and disability.

18 ility profiles and reasons for their reading disability.

19 e, which has been implicated in intellectual disability.

20 r disorder (BD) is a leading cause of global disability.

21 h schizophrenia who do not have intellectual disability.

22 y minor contributors to global mortality and disability.

23 s of age, lesion burden, and global clinical disability.

24 eurostimulation in stroke patients with gait disability.

25 ior to alemtuzumab in enabling recovery from disability.

26 arkinson's disease (PD), causing significant disability.

27 progression and preventing bowel damage and disability.

28 ntal gaze palsy, scoliosis, and intellectual disability.

29 ue, and their correlations with neurological disability.

30 with juvenile-onset ataxia and intellectual disability.

31 use an overgrowth syndrome with intellectual disability.

32 ociated with increased mortality and greater disability.

33 identify individuals at risk of future work disability.

34 d is linked to both obesity and intellectual disability.

35 muscle atrophy and infantile death or severe disability.

36 psychiatric disorders and causes substantial disability.

37 s by sex, socioeconomic status, and level of disability.

38 multiple sclerosis (MS) and MS activity and disability.

39 (ogen), and its potential impact on clinical disability.

40 yelination failure contributes to persistent disability.

41 ommon known inherited cause of developmental disability.

42 nt invasive GBS disease, (3) deaths, and (4) disabilities.

43 ly underserved groups, including people with disabilities.

44 hich are characterized by high morbidity and disabilities.

45 h implications for understanding mathematics disabilities.

46 um are common in children with developmental disabilities.

47 h and cause life-long cognitive and learning disabilities.

48 mes of interest were all-cause mortality and disability 1 year after the procedure.

49 k of sexual violence than were women without disabilities (11.0% vs 7.5%, OR 1.5; p=0.01).

50 sexual relationships than were women without disabilities (2.5% vs 0.5%, p=0.05).

51 f disaster as well as incidence of cognitive disability (82.1% follow-up rate).

52 RX-related disorders, including intellectual disability, abnormal genitalia, and structural CNS malfo

53 Ras mutations associated with intellectual disability abolished the spacing effect and led neurons

54 to become the leading cause of neurological disability across all age groups.

55 timate of US$94 (95% CrI: US$51, US$166) per Disability Adjusted Life Year (DALY) averted, PMI-funded

56 did EUC alone for the secondary outcomes of disability (adjusted mean difference -2.73 [-4.39 to -1.

57 eliable and valid prevalence, incidence, and disability-adjusted life year (DALY) estimates of oral c

58 ompared with UC was $3428.71 to $6857.68 per disability-adjusted life year avoided, and $0.80 to $1.6

59 burden of CT and cCMV in Belgium in terms of disability-adjusted life years (DALYs) and identify data

60 from passive vaping was derived by computing disability-adjusted life years (DALYs) lost due to expos

61 Disability-adjusted life years (DALYs), years lived with

62 16, 2012, to estimate the costs and cost per disability-adjusted life-year averted of introducing Xpe

63 d 103.1 million (90.8 million 115.1 million) disability-adjusted life-years (DALYs) in 2015, represen

64 No studies have estimated disability-adjusted life-years (DALYs) lost due to hip f

65 (YLLs), years lived with disability (YLDs), disability-adjusted life-years (DALYs), life expectancy,

66 tality from scabies, YLDs were equivalent to disability-adjusted life-years (DALYs).

67 aharan Africa will probably lose 2.3 million disability-adjusted life-years and US$3.5 billion of eco

68 stroke incidence, prevalence, mortality, and disability-adjusted life-years rates tend to decline fro

69 Changes in quality-adjusted life-years, disability-adjusted life-years, or survival and mortalit

70 re impaired functioning (measured by the WHO Disability Adjustment Schedule [WHODAS]), symptoms of po

71 Work disability affects quality of life, earnings, and opport

72 tcome measure was the shift in the degree of disability among the 2 groups as measured by the modifie

73 phase random sampling to recruit adults with disabilities and a control group matched for age, sex, a

74 utations shows evidence of specific learning disabilities and autism.

75 or older, with mild to moderate intellectual disabilities and clinically significant depression were

76 f clinical rehabilitation therapies to treat disabilities and complications of SCI.

77 ention (BeatIt) for people with intellectual disabilities and depression.

78 n (FMRP) from birth results in developmental disabilities and lifelong impairments.

79 l interventions for people with intellectual disabilities and mental health problems.

80 ial relevance in the context of intellectual disabilities and psychiatric disorders.Brain cytoplasmic

81 CIPN+ reported significantly more disability and 1.8 times the risk of falls compared with

82 .001) for eyes of children with intellectual disability and 21.93 (95% CI, 2.95-162.80; P = 0.003) fo

83 ZSWIM6 who have severe-profound intellectual disability and additional central and peripheral nervous

84 dual additionally presents with intellectual disability and autism spectrum disorder.

85 ame dose, compound 23 also reversed physical disability and cleared the brain of T-cell infiltration

86 eep and daytime alertness, causing premature disability and death.

87 ranscriptional regulation cause intellectual disability and developmental delay and are present in ap

88 (ALS) and developmental delay, intellectual disability and dysmorphic features.

89 dysfunction has been linked to intellectual disability and epilepsy.

90 1-like (MYT1L) gene in cases of intellectual disability and in the etiology of neurodevelopmental dis

91 arthritis (OA) is a common cause of pain and disability and is often associated with the degeneration

92 TNAL1 locus in humans result in intellectual disability and microcephaly suggest that KATNAL1 may pla

93 who display moderate to severe intellectual disability and microcephaly.

94 Walking disability and NSAIDs use have been postulated as potent

95 The British Society for Disability and Oral Health guidelines made recommendatio

96 into indirect and direct effects via walking disability and use of NSAIDs, respectively.

97 toms) to 6 (death) with categories 5 (severe disability) and 6 (death) collapsed into one category (s

98 ed in ADHD), ST3GAL3 (linked to intellectual disability) and PEX2 (related to perixosomal processes).

99 Outcomes were 14.5% mortality, 43.7% disability, and 9.8% deep vein thrombosis.

100 d by epileptic seizures, severe intellectual disability, and autistic features.

101 n glycosylation, short stature, intellectual disability, and cataracts, overlapping both the dystrogl

102 uld be associated with subsequent mortality, disability, and cognitive impairment, regardless of age.

103 ture, autism spectrum disorder, intellectual disability, and corpus callosum agenesis.

104 ain function, different pathogenic models of disability, and different possible treatments.

105 ory seizures, developmental delay, cognitive disability, and elevated risk of sudden unexpected death

106 sent one of the leading causes of mortality, disability, and health care costs worldwide.

107 resents the most frequent cause of death and disability, and it remains unclear why, of all body orga

108 higher average pain intensity, pain-related disability, and reduced physical health-related quality

109 ted with Pitt-Hopkins syndrome, intellectual disability, and schizophrenia (SCZ).

110 Outcomes were death, disability, and thromboembolic complications.

111 djusted life years (DALYs), years lived with disability, and years of life lost from 15 skin conditio

112 ranges from 0 [death] to 10 [no symptoms or disability]) and the rate of functional independence (a

113 a, cardiomyopathy, nonsyndromic intellectual disability, apoptosis, and the Warburg effect.

114 Age-associated disease and disability are placing a growing burden on society.

115 and financial burdens of chronic illness and disability are straining families and communities.

116 jury (TBI) is the leading cause of death and disability around the world and affects 1.7 million Amer

117 lity from 1988 to 2004, calling attention to disability as a cost of longer lifetime exposure to obes

118 Secondary outcomes included degree of disability assessed by overall distribution of the modif

119 stroke and 395 (6.7%) had MI with 1 or more disability assessment after the event.

120 SD-noID or DD suggests that the intellectual disability associated with ASD might be etiologically di

121 to HIV infection as well as the presence of disability-associated HIV infection.

122 urs after birth reduces the risk of death or disability at 18 months among infants with hypoxic-ische

123 ygen supplementation did not reduce death or disability at 3 months.

124 n clinical deficit and infarct, outcomes for disability at 90 days were better with thrombectomy plus

125 oxygen administration in reducing death and disability at 90 days, and if so, whether oxygen given a

126 6, with higher scores indicating more severe disability) at 90 days.

127 to 3, with higher scores indicating greater disability) at month 3.

128 to 3, with higher scores indicating greater disability) at the month 3 analysis.

129 terized by developmental delay, intellectual disability, ataxia, seizures and a happy affect.

130 The fraction of population disability attributable to obesity followed a similar tr

131 1 or more genes associated with intellectual disability, autism, and/or epilepsy were identified: 2p1

132 and included a test for different slopes of disability before and after the event.

133 The annual increase in disability before stroke (0.06 points per year; 95% CI,

134 alth, life dissatisfaction, and the need for disability benefits due to inability to work.

135 e some advantages for those who obtained SSA disability benefits over the 2-year treatment period, bu

136 e intervention did not reduce receipt of SSA disability benefits.

137 al, 0.25-0.63; P<0.001), absence of physical disability (beta coefficient=0.40; 95% confidence interv

138 s have been associated with the risk of work disability, but few multifactorial algorithms exist to i

139 f daily living (ADL)/instrumental ADL (IADL) disability, Centers for Epidemiologic Studies Depression

140 hypotonia, developmental delay, intellectual disability, congenital anomalies, characteristic facial

141 , in unrelated individuals with intellectual disability, congenital malformations, ophthalmologic ano

142 Although disability correlated with pain in isolation, it became

143 Current medical disability cost estimates from world conflicts continual

144 steoporotic fractures are a leading cause of disability, costs, and mortality.

145 ems to negatively impact on the longitudinal disability course.

146 e degree to which different kinds of reading disabilities (defined as profiles or patterns of reading

147 months, and had persistent and severe social disability, defined as engagement in less than 30 h per

148 isabled at baseline had 14.2% probability of disability developing during follow-up.

149 ration and the probability of vision-related disability developing during follow-up.

150 ar MS was associated with 34% higher odds of disability developing over time (odds ratio [OR], 1.34;

151 Here, we describe an intellectual disability disorder in ten individuals with inherited or

152 tor neuron disease and X-linked intellectual disability disorders, thus highlighting the necessity to

153 <1.99 mm3) had a 6.4-fold risk for worsening disability during follow-up compared with patients with

154 ted as predictive factors for development of disability during follow-up.

155 the probability of developing vision-related disability during follow-up.

156 t least 10000 (UR, 3000-27000) children with disability each year.

157 Frailty is a risk factor for death and disability following TAVR and SAVR.

158 mates disability prevalence and disabled and disability-free life expectancy by year.

159 rease in the association between obesity and disability from 1988 to 2004, calling attention to disab

160 n increasing association between obesity and disability has leveled off in more recent years, and is

161 In resource-limited settings, people with disabilities have been left behind in the response to HI

162 es autism spectrum disorder and intellectual disability; however, the neurobiological basis for this

163 sorder characterized by autism, intellectual disability, hyperactivity, and seizures.

164 ould contribute to the pain or even physical disability (i.e. joint erosions) in HEDS patients.

165 e NMD factor gene, UPF3B, cause intellectual disability (ID) and are strongly associated with autism

166 (CNVs) known to confer risk for intellectual disability (ID) and autism spectrum disorder (ASD) and a

167 chromosome, are associated with intellectual disability (ID) and autism spectrum disorder (ASD).

168 knowledge, the association with intellectual disability (ID) has not been investigated.

169 Intellectual disability (ID) is a clinically and genetically heteroge

170 Intellectual disability (ID) is a measurable phenotypic consequence o

171 Intellectual disability (ID) is a prevailing neurodevelopmental condi

172 ism spectrum disorder (ASD) and intellectual disability (ID), and frequently presents with attention

173 r (DAT) gene, leading to severe neurological disabilities in children and adults.

174 tus, thereby mitigating severe developmental disabilities in newborns.

175 t for treatments aimed at rescuing cognitive disabilities in patients with DS.

176 dihydroxyflavone at alleviating intellectual disabilities in the DS model.

177 railty Scale scores were not associated with disability in basic activities of daily living or with c

178 and these comorbidities add to the amount of disability in both sexes.

179 ral palsy describes the most common physical disability in childhood and occurs in 1 in 500 live birt

180 s the most frequent cause of severe physical disability in childhood.

181 ssociated with development of vision-related disability in glaucoma.

182 bifida, a common cause of severe neurologic disability in humans.

183 P < 0.001 at 12 mo) and with greater odds of disability in instrumental activities of daily living (P

184 D) is a leading cause of premature death and disability in low-income countries; however, few receive

185 00 people annually, while creating long-term disability in millions more.

186 uronal loss, a key substrate of irreversible disability in multiple sclerosis (MS), is a recognized f

187 ins different aspects of motor and cognitive disability in patients with progressive MS.

188 oke, which is the primary cause of long term disability in the United States and the second leading c

189 diseases are an important cause of death and disability in the United States.

190 demyelinating disease of the CNS that causes disability in young adults as a result of the irreversib

191 us (range, 0-4; higher scores indicate worse disability), incidence of osteonecrosis of the jaw, kidn

192 ould help to fulfil the "healthy lives" and "disability inclusive" goals in the UN's new 2030 Agenda

193 eline in the Health Assessment Questionnaire-Disability Index (HAQ-DI) score (scores range from 0 to

194 score on the Health Assessment Questionnaire-Disability Index (HAQ-DI; scores range from 0 to 3, with

195 ndpoint was a >/=50% improvement on the Pain Disability Index in 50% of patients with active DBS comp

196 ual Analogue Scale) and had an ODI (Oswestry Disability Index) of 60%.

197 of epilepsy (active or in remission), motor disability, intellectual disability, or statement of spe

198 nts with both schizophrenia and intellectual disability, it is also seen in patients with schizophren

199 ducation did not significantly decrease with disability level (P = .113).

200 The rates did not increase with disability level (P = .738, P = .134).

201 common odds ratio (OR) for a change from one disability level to the next better (lower) level; OR gr

202 s that this cohort had high baseline age and disability levels; the prognostic value of MSIS-29 for s

203 an IQ in the normal (>/=70) or intellectual disability (<70) range were calculated.

204 dary outcome measure at 1 year follow-up was disability, measured using the modified Rankin Scale (mR

205 spiratory functioning, along with absence of disability, mental health problems, and major chronic di

206 e individuals are strikingly similar: severe disability, microcephaly, hearing loss, spasticity, and

207 that discrete gene mutations in intellectual disability might generate "secondary" pathophysiological

208 The increase in disability near the time of the event was greater for st

209 icits and reproduces the essential cognitive disabilities of the human syndrome.

210 zure activity in adulthood, (2) intellectual disability of any degree, and (3) no structural brain ab

211 success, but lifespan extension might expand disability of physical and cognitive functioning as more

212 ead circumference >/=+2 SD) and intellectual disability (OGID).

213 coprimary end points were the mean score for disability on the utility-weighted modified Rankin scale

214 the United States and may lead to a range of disabilities or death.

215 (death) collapsed into one category (severe disability or death), analysed as the distribution of th

216 We determined type, severity, outcome (disability or death), and time course of bleeding requir

217 on and that led (or could have led) to major disability or death.

218 all-cause mortality through either a walking disability or NSAIDs use was 1.92 (95% CI: 0.86-4.26) an

219 lepsy was the only predictor of intellectual disability (OR 8.0, 95% CI 1.1-59.6).

220 n remission), motor disability, intellectual disability, or statement of special educational needs.

221 available at 12 months, thrombectomy reduced disability over the range of the mRS (common adjusted od

222 indings were obtained by adjusting for motor disability (P < .05, permutation-corrected P = .06).

223 to SD was associated with death (P = 0.007), disability (P = 0.012), and deep vein thrombosis (P = 0.

224 ture diagnosis-specific sickness absence and disability pension among women with breast cancer compar

225 iations between sleep apnea and receipt of a disability pension and mortality in a prospective study

226 associated with a higher risk of receiving a disability pension but not higher total mortality.

227 municipal support, sick leave benefits, and disability pension funds than the general population.

228 t relatively low future sickness absence and disability pension levels can be used by patients when p

229 women with inpatient sleep apnea received a disability pension.

230 ng early-onset epilepsy, severe intellectual disability, postnatal microcephaly, and movement disorde

231 ependently associated with frailty were IADL disability (PR, 3.22; 95% CI, 1.72-6.06), depressive sym

232 The model estimates disability prevalence and disabled and disability-free l

233 not anticoagulated, 166 (87.8%) had no major disability prior to the event and 167 (88.4%) had a high

234 difficulties of children with unique reading disability profiles and reasons for their reading disabi

235 gs across children with quite varied reading disability profiles that we hypothesize compound the dev

236 ollow-up and to analyze correlations between disability progression and RNFL degeneration.

237 nd point was the percentage of patients with disability progression confirmed at 12 weeks in a time-t

238 and until a prespecified number of confirmed disability progression events had occurred.

239 ercentage of patients with 24-week confirmed disability progression was 29.6% with ocrelizumab versus

240 ercentage of patients with 12-week confirmed disability progression was 32.9% with ocrelizumab versus

241 To assess disability, quality of life, and complications in patien

242 orted using the modified Rankin Scale score (disability range, 0 [no symptoms] to 6 [death]; minimum

243 people with disabilities than people without disabilities reflects a higher exposure to HIV infection

244 fatigue lasting >/=6 months with significant disabilities, related to an acute Q fever infection, wit

245 n [7%]; mean [SD] age, 34 [8] years), global disability, satisfaction with life, neurobehavioral symp

246 order severity was measured with the Sheehan Disability Scale.

247 1.20; P < .001) than MI (0.20 points on the disability scale; 95% CI, 0.06 to 0.35; P = .006).

248 t was greater for stroke (0.88 points on the disability scale; 95% CI, 0.57 to 1.20; P < .001) than M

249 ondary outcomes were the effect of drinking, disability score, days unable to work, suicide attempts,

250 Clinical disability scores (Expanded Disability Status Scale [p =

251 ttern of structural anomalies and functional disabilities secondary to central and, perhaps, peripher

252 feasible strategy to treat the intellectual disability seen in Kabuki syndrome and related disorders

253 lay (GDD), often accompanied by intellectual disability, seizures and other features is a severe, cli

254 rames, and informing healthcare, social, and disability service provision.

255 lthough both treatment groups suffered motor disability, slowed development and reduced cocoons.

256 locking plate fixation resulted in superior disability status at 6 months.

257 L was independently associated with Expanded Disability Status Scale (EDSS) assessments (beta = 1.105

258 alizumab), age 65 years or younger, Expanded Disability Status Scale (EDSS) score 6.5 or lower, and n

259 Expanded Disability Status Scale (EDSS) scores, disease duration,

260 osure decreased the risk of a first Expanded Disability Status Scale (EDSS)-worsening event (HR, 95%

261 Clinical disability scores (Expanded Disability Status Scale [p = 0.009] and Instituto de Pes

262 ortex was associated with increased Expanded Disability Status Scale scores in surface-based general

263 apses averaged 4 +/- 2.4, and their Expanded Disability Status Scale was 2.7 +/- 0.5.

264 titative neurological examination, including disability status, visual, cognitive, motor, and sensory

265 ed normally sighted controls to guide visual disability strategies in RP.

266 animal models of disorders with intellectual disability, such as Noonan syndrome.

267 6 independent families with an intellectual disability syndrome associated with seizures and dysmorp

268 rted as blepharophimosis-ptosis-intellectual disability syndrome).

269 y and a previously unrecognized intellectual disability syndrome.

270 r prevalence of HIV infection in people with disabilities than people without disabilities reflects a

271 incidence and experience greater poststroke disability than whites.

272 Learning disabilities that affect about 10% of human population a

273 major depression (MD) are leading causes of disability that often co-occur.

274 ventable and treatable cause of intellectual disability that should be considered in the early differ

275 ite in English or Danish, or had a cognitive disability that would preclude their understanding of th

276 cs might compress activities of daily living disability, that is, benefits of success, but lifespan e

277 ith schizophrenia who also have intellectual disability, this burden is concentrated in risk genes as

278 Moderate disability was defined as a cognitive score of 70 to 84

279 e predictive effect of self-reported hearing disability was modified by readiness such that with high

280 eurological deficit) or 2 (moderate cerebral disability) was considered a good functional outcome.

281 People with disabilities were also at increased risk of sexual viole

282 Women with disabilities were more often involved in paid sexual rel

283 Pain and pain-related disability were assessed with the chronic pain grade que

284 e sclerosis is a major cause of neurological disability, which accrues predominantly during progressi

285 ion results in a severe form of intellectual disability, which parallels mental deficits found in pat

286 ed childhood-onset epilepsy and intellectual disability who were recruited from the Toronto Western H

287 The number living with disability will increase by 25.0% (95% UI 21.3-28.2), fr

288 es and five males, and all have intellectual disability with delayed speech, a history of febrile and

289 6% posterior probability of reduced death or disability with hypothermia relative to the noncooled gr

290 novo variants in GRIA4 lead to intellectual disability with or without seizures, gait abnormalities,

291 ry (TBI) is a leading cause of morbidity and disability, with a considerable socioeconomic burden.

292 88%) were alive and free of major functional disability, with minimal clinical symptoms.

293 patients with mild to moderate intellectual disability, with or without epilepsy and behavioural dis

294 ences offspring risk of ASD and intellectual disability without autism (ID).

295 Leprosy, the leading infectious cause of disability worldwide, remains a major public health chal

296 nd is the fastest growing neurodevelopmental disability worldwide.

297 ors for a second clinical attack and a first disability-worsening event in pediatric clinically isola

298 ) that segregates with X-linked intellectual disability (XLID) in an affected family.

299 c brain injury is a major cause of death and disability, yet many predictors of outcome are not preci

300 years of life lost (YLLs), years lived with disability (YLDs), disability-adjusted life-years (DALYs